摘要
目的探讨罗沙司他对比促红细胞生成素治疗血液透析患者肾性贫血的有效性和安全性。方法计算机检索PubMed、Web of Science、Embase、Cochrane Library、知网、中国生物医学文献数据库、维普及万方数据库。检索时间从建立数据库起至2021年2月关于比较罗沙司他与促红细胞生成素治疗血液透析患者肾性贫血的随机对照研究。由2名研究者独立筛选文献、提取资料并进行文献质量评价。采用RevMan 5.4软件对纳入的研究进行Meta分析。结果共纳入3篇文献540例患者,与促红细胞生成素相比,罗沙司他可提高血红蛋白达标率(OR=2.82,95%CI 1.06~7.48,P=0.04),对血红蛋白水平的提高,两组差异无统计学意义(MD=-0.13,95%CI-0.46~0.20,P=0.43),罗沙司可显著提高总铁结合力(MD=35.07,95%CI 12.45~57.70,P=0.002),但罗沙司他组的不良事件发生率高于对照组(OR=1.98,95%CI 1.30~3.04,P=0.002)。结论罗沙司他可有效改善慢性肾脏病血液透析患者的贫血,但其安全性问题仍需广泛关注。
Objective To compare the efficacy and safety of roxadustat and erythropoietin in the treatment of renal anemia in hemodialysis patients.Methods Randomized controlled studies of roxadustat and erythropoiet regarding renal anemia in hemodialysis patients from PubMed,Web of Science,Embase,Cochrane Library,CNKI,CBM,VIP and WanFang Data were collected by two researchers,the conduction of the database is by February 2021;the extracted literature were evaluated the quality,and Revman 5.4 software was used for meta analysis.Results A total of 540 patients were included in three articles.In the comparison with the control group,the hemoglobin rate could be improved in roxadustat group(OR=2.82,95%CI 1.06~7.48,P=0.04),and there was no significant difference in the improvement of hemoglobin level between the two groups(MD=-0.13,95%CI-0.46~0.20,P=0.43).Roxadustat could significantly improve iron-binding capacity,(MD=35.07,95%CI 12.45-57.70,P=0.002),but the incidence of adverse events was higher in the roxadustat group than that in the control group(OR=1.98,95%CI 1.30-3.04,P=0.002).Conclusion Roxadustat can effectively reduce renal anemia in hemodialysis patients,but its safety still should be attention widely.
作者
周任
陈亚婷
张永
Zhou Ren;Chen Yating;Zhang Yong(Department of Nephrology, Taihe Hospital, affiliated Hospital of Hubei University of Medicine, Shiyan 442000, China)
出处
《临床荟萃》
CAS
2022年第4期305-310,共6页
Clinical Focus
